Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

  • Exchange: Toronto
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Specialty Pharma

Valeant Pharmaceuticals International Inc

+ Add to Watchlist

VRX:CN

291.180 CAD 5.950 2.09%

As of 13:31:57 ET on 05/22/2015.

Snapshot for Valeant Pharmaceuticals International Inc (VRX)

Open: 286.700 Day's Range: 284.920 - 292.960 Volume: 371,084
Previous Close: 285.230 52wk Range: 116.010 - 292.960 1-Yr Rtn: +104.15%

Stock Chart for VRX

No chart data available.
  • VRX:CN 291.310
  • 1D
  • 1M
  • 1Y
285.230
Interactive VRX Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for VRX

Current P/E Ratio (ttm) 86.4190
Estimated P/E(12/2015) 21.2603
Relative P/E vs. SPTSX 3.9482
Earnings Per Share (USD) (ttm) 2.7492
Est. EPS (USD) (12/2015) 11.1800
Est. PEG Ratio 1.2149
Market Cap (M CAD) 99,491.52
Shares Outstanding (M) 340.86
30 Day Average Volume 621,614
Price/Book (mrq) 12.5479
Price/Sale (ttm) 9.2718
Dividend Indicated Gross Yield -%
Cash Dividend (USD) 1.0000
Dividend Ex-Date 11/10/2010
5 Year Dividend Growth -
Next Earnings Announcement 07/31/2015
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for VRX

  • Revenue
  • Net Income (M/USD)
  • Profit Margin (%)

Company Profile & Key Executives for VRX

Valeant Pharmaceuticals International, Inc. develops and distributes drugs. The Company develops drugs for unmet medical needs in central nervous system disorders, and distributes generic and branded generic drugs in Latin America and Eastern Europe.

J Michael Pearson "Mike"Chairman/CEOAri S KellenGroup Chairman/Exec VP
Laizer D KornwasserGroup Chairman/Exec VPAnne C WhitakerGroup Chairman/Exec VP
More Company Profile & Key Executives for VRX

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil